StockData
HCW Biologics Inc. logo

HCW Biologics Inc. (HCWB) stock

HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)

Close on Nov 18, 2026Market cap $1.40MP/E –Yield –

HCW Biologics r&d expenses

Research and development expenses are spending on new products and technology.

HCW Biologics's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.20M, up 5.2% year over year. For fiscal 2025 it was $5.44M, down 14.8% from the year before. The highest annual figure on record is $9.34M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.44M-14.8%
FY2024Dec 31, 2024$6.39M-16.8%
FY2023Dec 31, 2023$7.68M-17.8%
FY2022Dec 31, 2022$9.34M+14.2%
FY2021Dec 31, 2021$8.17M+12.7%
FY2020Dec 31, 2020$7.26M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.20M-1.9%
Q1 FY2026Mar 31, 2026$1.26M-14.9%
Q4 FY2025Dec 31, 2025$1.33M+27.0%
Q3 FY2025Sep 30, 2025$1.40M+18.3%
Q2 FY2025Jun 30, 2025$1.23M-39.5%
Q1 FY2025Mar 31, 2025$1.48M-30.4%
Q4 FY2024Dec 31, 2024$1.05M-50.9%
Q3 FY2024Sep 30, 2024$1.19M-28.8%
Q2 FY2024Jun 30, 2024$2.03M+25.5%
Q1 FY2024Mar 31, 2024$2.12M-5.9%
Q4 FY2023Dec 31, 2023$2.14M-27.1%
Q3 FY2023Sep 30, 2023$1.67M-37.0%
Q2 FY2023Jun 30, 2023$1.62M-17.9%
Q1 FY2023Mar 31, 2023$2.26M+26.0%
Q4 FY2022Dec 31, 2022$2.93M+97.5%
Q3 FY2022Sep 30, 2022$2.65M-1.4%
Q2 FY2022Jun 30, 2022$1.97M+17.7%
Q1 FY2022Mar 31, 2022$1.79M-23.2%
Q4 FY2021Dec 31, 2021$1.48M+5.2%
Q3 FY2021Sep 30, 2021$2.69M+28.0%
Q2 FY2021Jun 30, 2021$1.67M-19.1%
Q1 FY2021Mar 31, 2021$2.33M–
Q4 FY2020Dec 31, 2020$1.41M–
Q3 FY2020Sep 30, 2020$2.10M–
Q2 FY2020Jun 30, 2020$2.07M–

More HCW Biologics figures

See a number that looks wrong?